According to a Competition and Markets Authority (CMA) investigation, between January 2013 and June 2016 the two companies agreed that Concordia (formerly Amdipharm) would not enter the market with its own version of hydrocortisone tablets.
Free to registered users
Register to gain full access to C+D and C+D Community content
Already registered?